Pulmovant is a Roivant-backed clinical-stage biotechnology company developing innovative therapies for patients suffering from pulmonary diseases. Pulmovant’s first program, mosliciguat is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is a novel, potential first-in-class, sGC activator with a differentiated mechanism that may have broad applicability across the PH spectrum. Mosliciguat has been extensively characterized across a robust Phase 1 program with 170 participants dosed to date including patients with PH in the Phase 1b ATMOS study which has produced highly compelling and clinically meaningful efficacy data, as well as a favorable safety profile. Enrollment in a phase 2 trial is ongoing. As part of the Roivant family of companies, Pulmovant leverages the power of collaboration and innovation to drive progress. For more information, please visit https://www.pulmovant.com . About Roivant: Roivant specializes in developing transformative medicines at an accelerated pace through the launch of nimble biopharmaceutical and health technology entities, each meticulously tailored to address a specific medical need. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 Vants; 12 consecutive positive Phase 3 trials; 8 FDA approvals; 5 successful IPOs; >$6B in capital raised; >$10B in global pharma partnerships and proceeds; and continued pipeline expansion across various modalities and therapeutic areas through in-licensing and acquisition of novel product candidates and technology platforms. In addition to a robust clinical stage pipeline, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. We are seeking a manager of CMC Analytical Development to help drive successful inhaled product development. The individual will work collaboratively with the Head of Analytical and cross-functionally within CMC to plan, track and report the release, stability and high-quality data packages to support regulatory submissions managed by CMC. This includes, but is not limited to, drug substance, drug product, analytical development, technical transfer, regulatory documentation, project strategy and vendor management. This is an exciting and visible role for a well-qualified and motivated individual. The successful candidate will be an analytical QC expert, with attention to detail and significant experience in analytical method transfer, release and stability testing in late clinical and commercial stage withing the biotechnology industry. The ideal candidate will be detail driven and have a proven track record in managing analytical activities contributing to project success of inhaled products in the pharma/biotech industry, preferably with experience in both small molecule and inhaled therapies.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level